Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (allo‐SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes. Results In a cohort of 152 patients undergoing allo‐SCT from 2012 to 2023, haploidentical donors with post‐transplant cyclophospham...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-04-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.70012 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849709897988440064 |
|---|---|
| author | Paul Jäger Benno Biermann Nora Liebers Felicitas Schulz Ben‐Niklas Baermann Sören Twarock Stefanie Geyh Kathrin Nachtkamp Patrick Tressin Annika Kasprzak Felix Matkey Titus Watrin Malika El Yaouti Ulrich Germing Sascha Dietrich Guido Kobbe |
| author_facet | Paul Jäger Benno Biermann Nora Liebers Felicitas Schulz Ben‐Niklas Baermann Sören Twarock Stefanie Geyh Kathrin Nachtkamp Patrick Tressin Annika Kasprzak Felix Matkey Titus Watrin Malika El Yaouti Ulrich Germing Sascha Dietrich Guido Kobbe |
| author_sort | Paul Jäger |
| collection | DOAJ |
| description | ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (allo‐SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes. Results In a cohort of 152 patients undergoing allo‐SCT from 2012 to 2023, haploidentical donors with post‐transplant cyclophosphamide (PTCy) showed superior survival compared to 9/10 mismatched unrelated donors (MMUD). Cox regression analysis revealed that patients not in complete remission (CR) before transplantation particularly benefited from haplo donors, while those with 9/10 MMUD and lacking CR had worse outcomes. Conclusion These results highlight the importance of donor selection, suggesting that haplo donors with PTCy may be preferable for patients not in CR, necessitating alternative approaches for others. Clinical trial registration The authors have confirmed clinical trial registration is not needed for this submission. |
| format | Article |
| id | doaj-art-d2288c8f3c2a462c8f7133195477db83 |
| institution | DOAJ |
| issn | 2688-6146 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj-art-d2288c8f3c2a462c8f7133195477db832025-08-20T03:15:05ZengWileyeJHaem2688-61462025-04-0162n/an/a10.1002/jha2.70012Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 PatientsPaul Jäger0Benno Biermann1Nora Liebers2Felicitas Schulz3Ben‐Niklas Baermann4Sören Twarock5Stefanie Geyh6Kathrin Nachtkamp7Patrick Tressin8Annika Kasprzak9Felix Matkey10Titus Watrin11Malika El Yaouti12Ulrich Germing13Sascha Dietrich14Guido Kobbe15Department of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyMedical Faculty and University Hospital Düsseldorf, Institute of Translational Pharmacology Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyDepartment of Hematology Oncology and Clinical Immunology Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf Duesseldorf GermanyABSTRACT Background Allogeneic hematopoietic stem cell transplantation (allo‐SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes. Results In a cohort of 152 patients undergoing allo‐SCT from 2012 to 2023, haploidentical donors with post‐transplant cyclophosphamide (PTCy) showed superior survival compared to 9/10 mismatched unrelated donors (MMUD). Cox regression analysis revealed that patients not in complete remission (CR) before transplantation particularly benefited from haplo donors, while those with 9/10 MMUD and lacking CR had worse outcomes. Conclusion These results highlight the importance of donor selection, suggesting that haplo donors with PTCy may be preferable for patients not in CR, necessitating alternative approaches for others. Clinical trial registration The authors have confirmed clinical trial registration is not needed for this submission.https://doi.org/10.1002/jha2.70012BMTcellular therapieshematological malignanciestransplant |
| spellingShingle | Paul Jäger Benno Biermann Nora Liebers Felicitas Schulz Ben‐Niklas Baermann Sören Twarock Stefanie Geyh Kathrin Nachtkamp Patrick Tressin Annika Kasprzak Felix Matkey Titus Watrin Malika El Yaouti Ulrich Germing Sascha Dietrich Guido Kobbe Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients eJHaem BMT cellular therapies hematological malignancies transplant |
| title | Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients |
| title_full | Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients |
| title_fullStr | Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients |
| title_full_unstemmed | Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients |
| title_short | Haploidentical Allogeneic Stem Cell Transplantation as a Superior Alternative for Patients With Mismatch Donors—A Single Center Experience in 152 Patients |
| title_sort | haploidentical allogeneic stem cell transplantation as a superior alternative for patients with mismatch donors a single center experience in 152 patients |
| topic | BMT cellular therapies hematological malignancies transplant |
| url | https://doi.org/10.1002/jha2.70012 |
| work_keys_str_mv | AT pauljager haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT bennobiermann haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT noraliebers haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT felicitasschulz haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT benniklasbaermann haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT sorentwarock haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT stefaniegeyh haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT kathrinnachtkamp haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT patricktressin haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT annikakasprzak haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT felixmatkey haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT tituswatrin haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT malikaelyaouti haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT ulrichgerming haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT saschadietrich haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients AT guidokobbe haploidenticalallogeneicstemcelltransplantationasasuperioralternativeforpatientswithmismatchdonorsasinglecenterexperiencein152patients |